Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2016 · 18 citations · 5 references
MedicinePharmacokineticsPharmacologyAntimicrobial PharmacotherapyClinical PharmacologyPharmacodynamicsCystic FibrosisCystic Fibrosis PharmacotherapyDrug DispositionPharmacokinetics Of AntimicrobialsAdult Cystic Fibrosis PharmacotherapyBlood Sample CollectionLower Limit Of QuantificationMethicillin-resistant Staphylococcus Aureus TreatmentPharmacodynamics In Cystic FibrosisPharmacodynamics Of AntibioticsPharmacokinetic ParametersPharmacokinetics In Cystic Fibrosis
STUDY OBJECTIVE: To evaluate the pharmacokinetics and pharmacodynamics of ceftaroline in adults with cystic fibrosis (CF). DESIGN: Open-label, single-center, prospective study. SETTING: University-affiliated teaching institution. PATIENTS: Eight patients with a diagnosis of CF and a history of methicillin-resistant Staphylococcus aureus who were treated with ceftaroline between November 2013 and September 2014. INTERVENTION: All patients received at least three doses of intravenous ceftaroline 600 mg every 12 hours, administered as a 60-minute infusion, to achieve steady-state concentrations before blood sample collection. After an interim analysis of the first four patients' pharmacokinetic data, the remaining four patients received a change in dosage of ceftaroline to 600 mg every 8 hours. MEASUREMENTS AND MAIN RESULTS: Patients' blood samples were collected at two time points, 2 and 6 hours after infusion initiation, after administration of at least three doses of ceftaroline. Serum ceftaroline concentrations were determined by using a validated mass spectrometry, with a lower limit of detection of 20 ng/ml. These ceftaroline concentrations were used to estimate patient-specific pharmacokinetic parameters, and 10,000-patient Monte Carlo simulations were performed to determine the pharmacodynamic probability of target attainment (PTA) for ceftaroline in adults with CF. A PTA of 90% or higher for the desired pharmacodynamic target was considered adequate. The PTA for 60% or higher of the dosing interval during which free (unbound) drug concentrations exceed the minimum inhibitory concentration (%fT > MIC) was simulated for various MICs. Compared with values previously reported in other populations, the volume of distribution was increased in the study patients, and the estimated half-life was shorter. Monte Carlo simulations revealed that a dose of ceftaroline 600 mg every 8 hours, infused over 60 minutes, maintained a higher than 90% PTA for %fT > MIC of 60% or higher for an MIC at the susceptibility breakpoint of 1 mg/L. CONCLUSION: The pharmacokinetics of ceftaroline is altered in adults with CF, which suggests the need for modified dosing in this patient population to achieve adequate %fT > MIC. A dosage of intravenous ceftaroline 600 mg every 8 hours administered as a 60-minute infusion should be considered to achieve 60% fT > MIC.
5
Pharmacokinetics of cefepime in cystic fibrosis patients
C E Huls, Randall A. Prince, Dan K. Seilheimer et al. · Antimicrobial Agents and Chemotherapy · 1993 · 32 citations · Full text
George G. Zhanel, E. Rossnagel, Kimberly A. Nichol et al. · Journal of Antimicrobial Chemotherapy · 2011 · 24 citations · Full text